An expanded analysis of pharmacogenetics determinants of Efavirenz response that includes 3'-UTR single nucleotide polymorphisms among black South African HIV/AIDS patients

Frontiers in Genetics

Volumn 6, Issue JAN, 2016, Pages

  Swart, Marelize ^a   Evans, Jonathan ^a   Skelton, Michelle ^a   Castel, Sandra ^a   Wiesner, Lubbe ^a   Smith, Peter J ^a   Dandara, Collet ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

3' UTR; Efavirenz; HIV AIDS; Pharmacogenetics; Sensitivity; Single nucleotide polymorphism; South Africa; Specificity

Indexed keywords

EFAVIRENZ;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84961652499     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2015.00356     Document Type: Article

References (89)

1. Abah, I. O., Akanbi, M., Abah, M. E., Finangwai, A. I., Dady, C. W., Falang, K. D., et al. (2015). Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. Germs 5, 83-91. doi: 10.11599/germs.2015.1075.
2. Adkins, J. C., and Noble, S. (1998). Efavirenz. Drugs 56, 1055-1064, Discussion: 1065-1056. doi: 10.2165/00003495-199856060-00014.
3. Arab-Alameddine, M., Di Iulio, J., Buclin, T., Rotger, M., Lubomirov, R., Cavassini, M., et al. (2009). Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin. Pharmacol. Ther. 85, 485-494. doi: 10.1038/clpt.2008.271.
4. Bae, S. K., Jeong, Y. J., Lee, C., and Liu, K. H. (2011). Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 41, 437-444. doi: 10.3109/00498254.2011.551849.
5. Bisaso, K. R., Mukonzo, J. K., and Ette, E. I. (2015). Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy. J. Clin. Pharmacol. 55, 1229-1235. doi: 10.1002/jcph.533.
6. Brown, K. C., Hosseinipour, M. C., Hoskins, J. M., Thirumaran, R. K., Tien, H. C., Weigel, R., et al. (2012). Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13, 113-121. doi: 10.2217/pgs.11.132.
7. Burger, D., van der Heiden, I., La Porte, C., van der Ende, M., Groeneveld, P., Richter, C., et al. (2006). Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61, 148-154. doi: 10.1111/j.1365-2125.2005.02536.x.
8. Burhenne, J., Matthée, A. K., Pasáková, I., Röder, C., Heinrich, T., Haefeli, W. E., et al. (2010). No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob. Agents Chemother. 54, 4185-4191. doi: 10.1128/AAC.00283-10.
9. Burk, O., Arnold, K. A., Nussler, A. K., Schaeffeler, E., Efimova, E., Avery, B. A., et al. (2005). Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67, 1954-1965. doi: 10.1124/mol.104.009019.
10. Cabrera, S. E., Santos, D., Valverde, M. P., Domínguez-Gil, A., Gonzalez, F., Luna, G., et al. (2009). Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob. Agents Chemother. 53, 2791-2798. doi: 10.1128/AAC.01537-08.
11. Cassetti, I., Madruga, J. V., Suleiman, J. M., Etzel, A., Zhong, L., Cheng, A. K., et al. (2007). The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials 8, 164-172. doi: 10.1310/hct0803-164.
12. Ciccacci, C., Borgiani, P., Ceffa, S., Sirianni, E., Marazzi, M. C., Altan, A. M., et al. (2010). Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 11, 23-31. doi: 10.2217/pgs.09.142.
13. Colic, A., Alessandrini, M., and Pepper, M. S. (2015). Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. Drug Metab. Rev. 47, 111-123. doi: 10.3109/03602532.2014.982864.
14. Colombo, S., Telenti, A., Buclin, T., Furrer, H., Lee, B. L., Biollaz, J., et al. (2006). Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Ther. Drug Monit. 28, 332-338. doi: 10.1097/01.ftd.0000211807.74192.62.
15. Cortes, C. P., Siccardi, M., Chaikan, A., Owen, A., Zhang, G., and La Porte, C. J. (2013). Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. Ther. Drug Monit. 35, 78-83. doi: 10.1097/FTD.0b013e318274197e.
16. Dhoro, M., Zvada, S., Ngara, B., Nhachi, C., Kadzirange, G., Chonzi, P., et al. (2015). CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe. BMC Pharmacol. Toxicol. 16:4. doi: 10.1186/s40360-015-0004-2.
17. Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., et al. (2015). Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs. 600 mg) in treatment-Naive HIV-infected patients: results of the ENCORE1 study. Clin. Pharmacol. Ther. 98, 406-416. doi: 10.1002/cpt.156.
18. di Iulio, J., Fayet, A., Arab-Alameddine, M., Rotger, M., Lubomirov, R., Cavassini, M., et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19, 300-309. doi: 10.1097/FPC.0b013e328328d577.
19. Elens, L., Vandercam, B., Yombi, J. C., Lison, D., Wallemacq, P., and Haufroid, V. (2010). Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11, 1223-1234. doi: 10.2217/pgs.10.94.
20. Evans, J., Swart, M., Soko, N., Wonkam, A., Huzair, F., and Dandara, C. (2015). A global health diagnostic for personalized medicine in resource-constrained world settings: a simple PCR-RFLP method for genotyping CYP2B6 g.15582C>T and science and policy relevance for optimal use of antiretroviral drug efavirenz. OMICS 19, 332-338. doi: 10.1089/omi.2015.0039.
21. Fumaz, C. R., Tuldra, A., Ferrer, M. J., Paredes, R., Bonjoch, A., Jou, T., et al. (2002). Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J. Acquir. Immune Defic. Syndr. 29, 244-253. doi: 10.1097/00042560-200203010-00004.
22. Gatanaga, H., Hayashida, T., Tsuchiya, K., Yoshino, M., Kuwahara, T., Tsukada, H., et al. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45, 1230-1237. doi: 10.1086/522175.
23. Gounden, V., van Niekerk, C., Snyman, T., and George, J. A. (2010). Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther. 7:32. doi: 10.1186/1742-6405-7-32.
24. Gross, R., Aplenc, R., Tenhave, T., Foulkes, A. S., Thakur, R., Mosepele, M., et al. (2008). Slow efavirenz metabolism genotype is common in Botswana. J. Acquir. Immune Defic. Syndr. 49, 336-337. doi: 10.1097/QAI.0b013e31817c1ed0.
25. Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3, 136-158. doi: 10.1038/sj.tpj.6500171.
26. Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lalama, C., Schackman, B. R., Meyer, W. A., et al. (2006). Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296, 769-781. doi: 10.1001/jama.296.7.769.
27. Haas, D. W. (2005). Will pharmacogenomic discoveries improve HIV therapeutics? Top. HIV Med. 13, 90-95.
28. Haas, D. W., Gebretsadik, T., Mayo, G., Menon, U. N., Acosta, E. P., Shintani, A., et al. (2009). Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J. Infect. Dis. 199, 872-880. doi: 10.1086/597125.
29. Haas, D. W., Kwara, A., Richardson, D. M., Baker, P., Papageorgiou, I., Acosta, E. P., et al. (2014a). Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J. Antimicrob. Chemother. 69, 2175-2182. doi: 10.1093/jac/dku110.
30. Haas, D. W., Ribaudo, H. J., Kim, R. B., Tierney, C., Wilkinson, G. R., Gulick, R. M., et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study. AIDS 18, 2391-2400.
31. Haas, D. W., Severe, P., Jean Juste, M. A., Pape, J. W., and Fitzgerald, D. W. (2014b). Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. J. Antimicrob. Chemother. 69, 2187-2190. doi: 10.1093/jac/dku088.
32. Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbe, L., et al. (2005). Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192, 1931-1942. doi: 10.1086/497610.
33. Hawkins, T., Geist, C., Young, B., Giblin, A., Mercier, R. C., Thornton, K., et al. (2005). Comparison of neuropsychiatric side effects in an observational cohort of efavirenz-and protease inhibitor-treated patients. HIV Clin. Trials 6, 187-196. doi: 10.1310/92VR-FP24-J8GA-B49Q.
34. Healan-Greenberg, C., Waring, J. F., Kempf, D. J., Blomme, E. A., Tirona, R. G., and Kim, R. B. (2008). A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab. Dispos. 36, 500-507. doi: 10.1124/dmd.107.019547.
35. Holzinger, E. R., Grady, B., Ritchie, M. D., Ribaudo, H. J., Acosta, E. P., Morse, G. D., et al. (2012). Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet. Genomics. 22, 858-867. doi: 10.1097/FPC.0b013e32835a450b.
36. Ikediobi, O., Aouizerat, B., Xiao, Y., Gandhi, M., Gebhardt, S., and Warnich, L. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum. Genomics 5, 265-282. doi: 10.1186/1479-7364-5-4-265.
37. Jamshidi, Y., Moreton, M., McKeown, D. A., Andrews, S., Nithiyananthan, T., Tinworth, L., et al. (2010). Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J. Antimicrob. Chemother. 65, 2614-2619. doi: 10.1093/jac/dkq369.
38. Kenedi, C. A., and Goforth, H. W. (2011). A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 15, 1803-1818. doi: 10.1007/s10461-011-9939-5.
39. Kim, J. Y., Cheong, H. S., Park, B. L., Kim, L. H., Namgoong, S., Kim, J. O., et al. (2014). Comprehensive variant screening of the UGT gene family. Yonsei Med. J. 55, 232-239. doi: 10.3349/ymj.2014.55.1.232.
40. Klein, K., Lang, T., Saussele, T., Barbosa-Sicard, E., Schunck, W. H., Eichelbaum, M., et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15, 861-873. doi: 10.1097/01213011-200512000-00004.
41. Lee, S. S., To, K. W., Lee, M. P., Wong, N. S., Chan, D. P., Li, P. C., et al. (2014). Sleep quality in efavirenz-treated Chinese HIV patients-comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms. Int. J. STD AIDS 25, 193-200. doi: 10.1177/0956462413498581.
42. Leutscher, P. D., Stecher, C., Storgaard, M., and Larsen, C. S. (2013). Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand. J. Infect. Dis. 45, 645-651. doi: 10.3109/00365548.2013.773067.
43. Li, J., Menard, V., Benish, R. L., Jurevic, R. J., Guillemette, C., Stoneking, M., et al. (2012). Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics 13, 555-570. doi: 10.2217/pgs.11.160.
44. Li, Z., Zhang, Z., He, Z., Tang, W., Li, T., Zeng, Z., et al. (2009). A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 19, 519-523. doi: 10.1038/cr.2009.33.
45. Lubomirov, R., Colombo, S., di Iulio, J., Ledergerber, B., Martinez, R., Cavassini, M., et al. (2011). Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis. 203, 246-257. doi: 10.1093/infdis/jiq043.
46. Maimbo, M., Kiyotani, K., Mushiroda, T., Masimirembwa, C., and Nakamura, Y. (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur. J. Clin. Pharmacol. 68, 267-271. doi: 10.1007/s00228-011-1118-0.
47. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., and Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75. doi: 10.1097/00002030-200101050-00011.
48. Mehlotra, R. K., Bockarie, M. J., and Zimmerman, P. A. (2007). CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br. J. Clin. Pharmacol. 64, 391-395. doi: 10.1111/j.1365-2125.2007.02884.x.
49. Mehlotra, R. K., Ziats, M. N., Bockarie, M. J., and Zimmerman, P. A. (2006). Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur. J. Clin. Pharmacol. 62, 267-275. doi: 10.1007/s00228-005-0092-9.
50. Moyle, G. (1999a). Efavirenz: practicalities, considerations and new issues. Int. J. Clin. Pract. Suppl. 103, 30-34.
51. Moyle, G. J. (1999b). Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Expert Opin. Investig. Drugs 8, 473-486.
52. Mukonzo, J. K., Okwera, A., Nakasujja, N., Luzze, H., Sebuwufu, D., Ogwal-Okeng, J., et al. (2013). Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect. Dis. 13:261. doi: 10.1186/1471-2334-13-261.
53. Mukonzo, J. K., Owen, J. S., Ogwal-Okeng, J., Kuteesa, R. B., Nanzigu, S., Sewankambo, N., et al. (2014). Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes. PLoS ONE 9:e86919. doi: 10.1371/journal.pone.0086919.
54. Mukonzo, J. K., Röshammar, D., Waako, P., Andersson, M., Fukasawa, T., Milani, L., et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br. J. Clin. Pharmacol. 68, 690-699. doi: 10.1111/j.1365-2125.2009.03516.x.
55. Naidoo, P., Chetty, V. V., and Chetty, M. (2014). Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur. J. Clin. Pharmacol. 70, 379-389. doi: 10.1007/s00228-013-1634-1.
56. Ngaimisi, E., Habtewold, A., Minzi, O., Makonnen, E., Mugusi, S., Amogne, W., et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS ONE 8:e67946. doi: 10.1371/journal.pone.0067946.
57. Nolan, D., Phillips, E., and Mallal, S. (2006). Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. Clin. Infect. Dis. 42, 408-410. doi: 10.1086/499369.
58. Nyakutira, C., Röshammar, D., Chigutsa, E., Chonzi, P., Ashton, M., Nhachi, C., et al. (2008). High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur. J. Clin. Pharmacol. 64, 357-365. doi: 10.1007/s00228-007-0412-3.
59. Ogburn, E. T., Jones, D. R., Masters, A. R., Xu, C., Guo, Y., and Desta, Z. (2010). Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38, 1218-1229. doi: 10.1124/dmd.109.031393.
60. Parathyras, J., Gebhardt, S., Hillermann-Rebello, R., Grobbelaar, N., Venter, M., and Warnich, L. (2009). A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J. Hum. Genet. 54, 261-265. doi: 10.1038/jhg.2009.20.
61. Penzak, S. R., Kabuye, G., Mugyenyi, P., Mbamanya, F., Natarajan, V., Alfaro, R. M., et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8, 86-91. doi: 10.1111/j.1468-1293.2007.00432.x.
62. Poeta, J., Linden, R., Antunes, M. V., Real, L., Menezes, A. M., Ribeiro, J. P., et al. (2011). Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. J. Antimicrob. Chemother. 66, 2601-2604. doi: 10.1093/jac/dkr360.
63. Raffi, F., Pozniak, A. L., and Wainberg, M. A. (2014). Has the time come to abandon efavirenz for first-line antiretroviral therapy? J. Antimicrob. Chemother. 69, 1742-1747. doi: 10.1093/jac/dku058.
64. Rotger, M., Lubomirov, R., Rodriguez-Novoa, S., and Barreiro, P. (2006). [Pharmacogenetics of antiretroviral therapy.]. Enferm. Infecc. Microbiol. Clin. 24(Suppl. 2), 13-18. doi: 10.1157/13096045.
65. Rotger, M., Tegude, H., Colombo, S., Cavassini, M., Furrer, H., Décosterd, L., et al. (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81, 557-566. doi: 10.1038/sj.clpt.6100072.
66. Rotger, M., and Telenti, A. (2008). Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur. J. Clin. Pharmacol. 64, 335-336. doi: 10.1007/s00228-007-0440-z.
67. Sanchez Martin, A., Cabrera Figueroa, S., Cruz Guerrero, R., Hurtado, L. P., Hurle, A. D., and Carracedo Alvarez, A. (2013). Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14, 1167-1178. doi: 10.2217/pgs.13.111.
68. Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., et al. (2013). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J. Antimicrob. Chemother. 69, 491-499. doi: 10.1093/jac/dkt372.
69. Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., et al. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J. Antimicrob. Chemother. 69, 491-499. doi: 10.1093/jac/dkt372.
70. Schackman, B. R., Haas, D. W., Park, S. S., Li, X. C., and Freedberg, K. A. (2015). Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. Pharmacogenomics 16, 2007-2018. doi: 10.2217/pgs.15.142.
71. Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., et al. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J. Antimicrob. Chemother. 66, 1332-1339. doi: 10.1093/jac/dkr087.
72. Shi, Y. Y., and He, L. (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15, 97-98. doi: 10.1038/sj.cr.7290272.
73. Sinxadi, P. Z., Leger, P. D., McIlleron, H. M., Smith, P. J., Dave, J. A., Levitt, N. S., et al. (2015). Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br. J. Clin. Pharmacol. 80, 146-156. doi: 10.1111/bcp.12590.
74. Ståhle, L., Moberg, L., Svensson, J. O., and Sönnerborg, A. (2004). Efavirenz plasma concentrations in HIV-infected patients: inter-and intraindividual variability and clinical effects. Ther. Drug Monit. 26, 267-270. doi: 10.1097/00007691-200406000-00008.
75. Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., et al. (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir. Ther. 13, 675-685.
76. Sukasem, C., Manosuthi, W., Koomdee, N., Santon, S., Jantararoungtong, T., Prommas, S., et al. (2014). Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Infection 42, 469-474. doi: 10.1007/s15010-013-0560-6.
77. Swart, M., and Dandara, C. (2014). Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance. Front. Genet. 5:167. doi: 10.3389/fgene.2014.00167.
78. Swart, M., Ren, Y., Smith, P., and Dandara, C. (2012a). ABCB1 4036A>G and 1236C>T polymorphisms affect plasma efavirenz levels in South African HIV/AIDS patients. Front. Genet. 3:236. doi: 10.3389/fgene.2012.00236.
79. Swart, M., Skelton, M., Ren, Y., Smith, P., Takuva, S., and Dandara, C. (2013). High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet. Genomics 23, 415-427. doi: 10.1097/FPC.0b013e328363176f.
80. Swart, M., Skelton, M., Wonkam, A., Kannemeyer, L., Chin'Ombe, N., and Dandara, C. (2012b). CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 polymorphisms in two bantu-speaking populations from cameroon and South Africa: implications for global pharmacogenetics. Curr. Pharmacogenomics Person. Med. 10, 43-53. doi: 10.2174/1875692111201010043.
81. Swart, M., Whitehorn, H., Ren, Y., Smith, P., Ramesar, R. S., and Dandara, C. (2012c). PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med. Genet. 13:112. doi: 10.1186/1471-2350-13-112.
82. ter Heine, R., Scherpbier, H. J., Crommentuyn, K. M., Bekker, V., Beijnen, J. H., Kuijpers, T. W., et al. (2008). A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir. Ther. 13, 779-787.
83. Tian, J. N., Ho, I. K., Tsou, H. H., Fang, C. P., Hsiao, C. F., Chen, C. H., et al. (2012). UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 13, 879-888. doi: 10.2217/pgs.12.69.
84. UNAIDS (2013). Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS.
85. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., and Desta, Z. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306, 287-300. doi: 10.1124/jpet.103.049601.
86. Ward, D. J., and Curtin, J. M. (2006). Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 20, 542-548. doi: 10.1089/apc.2006.20.542.
87. Wyen, C., Hendra, H., Siccardi, M., Platten, M., Jaeger, H., Harrer, T., et al. (2011). Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66, 2092-2098. doi: 10.1093/jac/dkr272.
88. Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., et al. (2008). Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61, 914-918. doi: 10.1093/jac/dkn029.
89. Zhang, W. X., Chen, B., Jin, Z., Yu, Z., Wang, X., Chen, H., et al. (2008). Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. Xenobiotica 38, 1422-1436. doi: 10.1080/00498250802488585.